Why immunotherapy might prevent neurodegeneration

Neurodegeneration results from the spread of misfolded aggregated proteins through the brain. Monoclonal antibodies that target the proteins might therefore reduce the load of misfolded aggregated protein and slow neurodegeneration, explained experts at MDS Virtual Congress 2020.

The most common neurodegenerative disorders are associated with protein aggregates,1 which appear to be pathologic rather than reactive,2 said Professor Andrew Siderowf, Pennsylvania, USA.

The protein aggregates appear to be pathogenic and not reactive

Progression of the neurodegeneration results from spread of the misfolded proteins through the brain, which also spread throughout the body, he added. Monoclonal antibodies that target the proteins may therefore reduce aggregate load and slow clinical progression in neurodegenerative disease.3

 

Prion-like spread throughout the body

Mice injected with intracerebral α-synuclein develop α-synuclein aggregates far away from the injection sites,4 said Professor Siderowf.

Could spread begin in the enteric nervous system?

In humans, α-synuclein aggregates have been described in:

  • salivary glands5
  • colonic biopsies up to 5 years before a diagnosis of Parkinson's disease6
  • healthy appendix7

The identification of α-synuclein pathology in these gastrointestinal-associated organs has led to the speculation that α-synuclein aggregates first develop in and then spread from the enteric nervous system.8

The spread of protein aggregates throughout the body has been compared to that of a prion—the proteins misfold into fibrils, propagate, and spread to adjacent neurons via dendrites and other neuronal connections,1,9 explained Professor Siderowf.

Spread is neuronal rather than anatomic

Distinct strains of the protein aggregates can be demonstrated; and spread and disease development appear to depend on the strain.10

 

Predictable course of spread through the brain

The spread of the α-synuclein aggregates through the brain follows a predictable course in PD, added Professor Siderowf.

α-synuclein aggregation is first identified in the dorsal motor nucleus of the glossopharyngeal and vagal nerves and anterior olfactory nucleus. It subsequently involves the brainstem, then the midbrain, and finally the neocortex.11

 

Identification and targeting of protein aggregates

Identification and targeting of protein aggregates is an exciting prospect for future diagnostic methods and treatments for neurodegenerative disorders.

Antibodies could block cell to cell spread

Professor Siderowf highlighted that early studies have shown that two protein amplification assays—the Protein-Misfolding Cyclic Amplification (PMCA) and the Real-Time Quaking-Induced Conversion (RT-QuIC) assays—have high sensitivity and specificity for detecting misfolded protein aggregates.

They therefore have the potential to identify people likely to develop synucleinopathies,12 said Professor Siderowf.

Given the significance of different aggregate strains, these biologic assays also have the potential to distinguish between PD and Parkinson’s-plus syndromes.13

 

For the latest updates on sea.progress.im, subscribe to our Telegram Channel https://bit.ly/telePiM

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. Uemura N, et al. Trends Mol Med. 2020; https://doi.org/10.1016/j.molmed.2020.03.012.
  2. Mullan M, et al. Nat Genet. 1992;1:345–7.
  3. Sevigny J, et al. Nature. 2016;537,50–6.
  4. Luk KC, et al. J Exp. Med. 2012;209:975–86.
  5. Beach TG, et al. J Neuropathol Exp Neurol. 2013;72:130–6.
  6. Shannon KM, et al. Mov Disord. 2012;27:716–9.
  7. Killinger BA, et al. Sci Transl Med. 2018;10:doi.10.1126/scitranslmed.aar5280.
  8. Del Tredici K, Braak H. Neuropathol Appl Neurobiol. 2016;42:33–50.
  9. Volpicelli-Daley LA, et al. Neuron 2011;72:57–71.
  10. Peng C, et al. Nature. 2018;557:558–63.
  11. Braak H, et al. Neurobiol. Aging 2003;24:197–211.
  12. Paciotti S, et al. Front. Neurol. June 2018:https://doi.org/10.3389/fneur.2018.00415.
  13. Shahnawaz M, et al. Nature. 2020;578:273–7.
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country